The company has 10 employees.At the center of the disorder is a gene called"WW domain containing oxidoreductase," or WWOX, that encodes for a protein that plays a role in brain development. When that protein is deficient, it causes WOREE syndrome, or"WWOX-related epileptic encephalopathy."Children diagnosed with the extremely rare mutation can develop seizures that can't be treated by drugs — what's known as refractory epilepsy.
With its MZ-9138 program, Mahzi looks to change that prognosis for children with WOREE as well as those with a slightly less severe form which presents at around 10-12 months of age. Mahzi is making the vector, an adeno-associated virus, and will start investigational new drug studies once it is ready, Weiss said. It could be in the clinic in 2024.
Mahzi's patient foundation and academic collaborations also are clear with the other two programs it has disclosed on its website.
대한민국 최근 뉴스, 대한민국 헤드 라인
Similar News:다른 뉴스 소스에서 수집한 이와 유사한 뉴스 기사를 읽을 수도 있습니다.
출처: SFBusinessTimes - 🏆 78. / 68 더 많은 것을 읽으십시오 »
출처: SFBusinessTimes - 🏆 78. / 68 더 많은 것을 읽으십시오 »
출처: svbizjournal - 🏆 334. / 59 더 많은 것을 읽으십시오 »
출처: CNBC - 🏆 12. / 72 더 많은 것을 읽으십시오 »